ArticleMediators of inflammation2014
Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.
Article in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: A systematic literature review.Medicine · 2017Pooled it
- Management of Severe Behçet's Disease.Current rheumatology reports · 2026Review
- Treatment of ocular sarcoidosis. Study of 65 patients from a series of 342 from a university hospital in northern Spain.International ophthalmology · 2025Article
- Efficacy of biologic and targeted synthetic disease-modifying antirheumatic drugs in non-infectious uveitis in axial spondyloarthropathy and their ocular side effects.Reumatologia · 2025Review
- Use of immunomodulators in non-infectious uveitis: lights and shadows.Eye (London, England) · 2024Review
- Efficacy of golimumab in patients with refractory non-infectious panuveitis.Scientific reports · 2024Article
- Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non-infectious uveitis.Clinical & translational immunology · 2023Review
- The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis.Inflammopharmacology · 2022Article
- TNF-α in Uveitis: From Bench to Clinic.Frontiers in pharmacology · 2021Review
- Biotherapies in Uveitis.Journal of clinical medicine · 2020Review
- Ocular toxicity of intravitreal golimumab in a rabbit modelTurkish journal of medical sciences · 2020Article
- Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies.International journal of ophthalmology · 2020Article
- Psoriasis and uveitis: links and risks.Psoriasis (Auckland, N.Z.) · 2019Article
- A case of human leukocyte antigen B-27-associated ocular hypotony successfully treated with golimumab.Indian journal of ophthalmology · 2018Article
- Cytokines in uveitis.Current opinion in ophthalmology · 2018Review
- Management of chronic ocular sarcoidosis: challenges and solutions.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future.BioMed research international · 2018Review
- Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease.Clinical rheumatology · 2017Article
- Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis.International ophthalmology · 2017Article
- Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.Clinical rheumatology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy.
methodsNonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients.
resultsEight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P = 0.009) and mean 1 mm central retinal thickness (317 versus 261.2 μ, P = 0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed.
conclusionsGLM is a new and promising therapeutic option for patients with severe and refractory uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.